H.C. Wainwright downgraded CalciMedica (CALC) to Neutral from Buy without a price target The immediate discontinuation for the Phase 2 KOURAGE clinical trial in acute kidney injury removes a major catalyst for the shares, the analyst tells investors in a research note. The firm looks to upcoming safety and population clarity as the company reviews the unblinded dataset to determine a potential path forward.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CALC: